首页|2例吡非尼酮治疗新型冠状病毒肺炎后肺纤维化的疗效分析

2例吡非尼酮治疗新型冠状病毒肺炎后肺纤维化的疗效分析

扫码查看
目的 观察并分析吡非尼酮治疗新冠病毒肺炎后肺纤维化的疗效.方法 收集我院2例重型新冠肺炎后肺间质纤维化患者就诊的临床资料,分析吡非尼酮运用于抗新冠肺炎后纤维化治疗的疗效.结果 2例分别患者经吡非尼酮治疗15周和9周后,动态复查胸部CT显示两例患者肺纤维化程度均较前明显减轻.结论 吡非尼酮可能在改善新冠病毒肺炎后肺纤维化预后方面具有一定疗效,但仍需更长时间的随访及更大样本的临床研究加以明确.
Effect of pirfenidone on pulmonary interstitial fibrosis after COVID-19 in 2 cases
Objective To observe and analyze the therapeutic effect of pirfenidone on pulmonary interstitial fibrosis secondary to COVID-19.Methods Clinical data of 2 patients with pulmonary interstitial fibrosis after severe COVID-19 were collected and followed up after discharged from our hospital,and the therapeutic effect of pirfenidone on anti-fibrosis secondary to COVID-19 was analyzed.Results After the two patients were treated with pirfenidone for 15 weeks and 9 weeks respectively,dynamic review of chest CT showed that the degree of pulmonary fibrosis in both patients was significantly reduced.Conclusions Pirfenidone may be effective in improving pulmonary fibrosis after COVID-19,but it still needs to be confirmed by longer duration of follow-up and clinical studies with more samples.

Novel coronavirus 2019Coronavirus disease 2019Pulmonary fibrosisPirfenidone

王霞、李家意、卢惠芬、崔海燕

展开 >

南方医科大学第三附属医院呼吸内科,广州 510630

新型冠状病毒 新型冠病毒肺炎 肺纤维化 吡非尼酮

2024

中国临床解剖学杂志
中国解剖学会

中国临床解剖学杂志

CSTPCD北大核心
影响因子:0.7
ISSN:1001-165X
年,卷(期):2024.42(3)
  • 1